ENZAMET, 2019 NCT02446405
enzalutamide plus ADT (n=-9) vs. androgen deprivation therapy (ADT) (n=-9)
randomized controlled trial
enzalutamide plus testosterone suppression
standard nonsteroidal antiandrogen therapy
(bicalutamide, nilutamide, or flutamide)
metastatic, hormone-sensitive prostate cancer
ARCHES, 2022 NCT02677896
enzalutamide plus ADT (n=574) vs. androgen deprivation therapy (ADT) (n=576)
randomized controlled trial
metastatic, hormone-sensitive prostate cancer